查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1806134

生物防御市场按产品类型、病原体类型、技术、应用、最终用户和分销管道划分—2025-2030 年全球预测

Biodefense Market by Product Type, Pathogen Type, Technology, Application, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计生物防御市场规模到 2024 年将达到 203.3 亿美元，到 2025 年将达到 227.1 亿美元，到 2030 年将达到 387.7 亿美元，复合年增长率为 11.35%。

主要市场统计数据
基准年2024年 203.3亿美元
预计2025年 227.1亿美元
预测年份 2030 387.7亿美元
复合年增长率（%） 11.35%

在这个生物威胁以前所未有的速度和隐蔽性出现和传播的时代，全面了解生物防御生态系统比以往任何时候都更重要。全球社会面临自然爆发、意外洩漏以及病原体的蓄意恶意使用等风险，迫切需要製定强有力的检测、预防和应对策略。这项背景促使政府、产业和科学研究相关人员加快对下一代技术和协作框架的投资，以弥补生物防御价值链各个环节的漏洞。

本执行摘要提炼了重新定义防范措施领域最突出的发展，包括产品创新、政策转变、供应链韧性和策略伙伴关係。透过对转型动态、贸易政策影响、细分领域洞察和区域差异进行结构化分析，本摘要提供了决策者如何针对新兴生物威胁情境协调资源和能力的整体观点。

本简报透过追溯技术进步与监管调整之间的相互关係，为领导者提供了清晰的行动蓝图。它也强调了公私协同和国际合作将如何塑造未来几年的机制。由此，它为随后的详细策略建议、调查方法揭露和结论奠定了基础，使各组织能够在快速变化的风险环境中加强防范，提升韧性。

确定重新定义生物防御准备能力和整个价值链产业协作的关键变革动力

生物防御领域正被一波突破性的技术创新和新颖的协作模式再形成，这些创新和模式正在重新定义威胁侦测和回应的可能性。合成生物学和基因编辑技术的进步提供了更灵敏的诊断平台，而人工智慧和机器学习则优化了预测分析，并加速了新兴病原体的识别。这些技术突破并非孤立存在；它们正被整合到物联网和云端基础架构中，建构一个无缝的即时监控和快速情境察觉网路。

全面评估2025年美国关税调整对生物防御采购和供应链的影响。

美国宣布的2025年新关税将对生物防御供应链、筹资策略和国内製造业奖励产生深远影响。关键原料、诊断设备和专用试剂的进口关税将上调，直接影响国际供应商和下游整合商的成本结构。这些贸易政策变化迫使企业重新评估供应商关係、成本谈判和库存管理实践，以减轻关税上调和物流延误的影响。

揭示产品类型、病原体、类别、技术、应用、最终用户和分销管道的关键细分观点

生物防御市场从多方面进行分析，包括产品类型、病原体类别、技术平台、应用领域、最终用户概况和分销模式。在产品频谱内，净化解决方案分为表面消毒剂和个人防护设备，提供防止污染的第一道防线。检测平台涵盖生物感测器阵列和病原体检测系统，每种平台均针对快速、现场可部署的筛检或高通量实验室诊断量身定制。治疗药物包括抗病毒和单株抗体疗法、小分子介入措施以及为精准标靶化设计的生物製药。疫苗製剂包括炭疽菌、肉毒桿菌和天花疫苗，每种疫苗均针对特定的生物威胁情境和免疫学特征量身打造。

重点介绍美洲、欧洲、中东和非洲以及亚太地区的主要区域差异和战略生物防御重点

受威胁认知、预算分配和基础设施能力差异的影响，生物防御领域的区域动态差异巨大。在美洲，现有的国防计画和大量的联邦研究津贴支撑着一个由国家实验室和国内製造商组成的强大网路。该地区在疫苗开发、治疗研究和诊断平台创新方面的主导地位得益于学术中心和商业实体之间的深度整合。具有全球影响力的监管机构的存在进一步加速了关键应对措施的核准和国际部署。

创新和合作伙伴关係塑造竞争格​​局；企业策略倡议

领先的生物防御产业公司以其多元化的创新、伙伴关係和商业化方法而闻名。大型製药企业正在利用其先进的生物加工能力和良好的监管记录，增加对下一代疫苗平台、抗体工程和抗病毒药物开发的关注。这些成熟的公司正在与规模较小的专业技术供应商建立策略联盟，以加快开发週期并扩大其全球影响力。

加强生物防御生态系统的弹性、敏捷性和联合准备的可行策略建议

为了加强生物防御准备并推动持续创新，各组织机构应采取多管齐下的策略，重点关注早期检测、供应链稳健性和协作情报。首先，投资先进的诊断平台，例如高通量测序和人工智慧驱动的生物感测器网络，可以更快地识别威胁并更准确地追踪流行病学。将这些技术嵌入分散式检查中心，可以进一步扩大侦测覆盖范围并减少回应延迟。

收集数据以洞察生物防御市场。采用结合专家咨询和严格分析架构的深入调查方法。

我们的分析基于一个全面的研究框架，该框架融合了行业专家的一手资料研究和严谨的二手资料收集。我们最初的二手资料研究包括系统性地回顾同行评审的出版物、政府白皮书、监管文件和专利资料库，以识别基本趋势和新兴技术。这些竞争考察与详细的公司概况和财务揭露相辅相成，从而揭示当前的竞争动态和投资流向。

关于未来发展轨蹟的总结：优先考虑全球生物防御领域的准备和新创新

随着全球威胁情势的不断演变，制定一个协调一致、灵活的生物防御策略的需求比以往任何时候都更加迫切。技术进步、贸易政策的转变以及区域优先事项的动态变化，要求我们采取一种能够连接检测、预防和回应的综合方法。能够成功将先进的诊断平台与弹性供应链模型和灵活监管途径结合的组织，将最有能力应对已知和新兴的生物风险。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 扩展人工智慧驱动的病原体检测平台，实现即时生物防御监测
  • 合成生物投资激增，疫苗开发平臺加速
  • 引进现场移动实验室，提升现场应变能力
  • 将基因组监测网络纳入国家预警系统
  • 加强国防机构与生物製药公司在对策研发方面的合作
  • 过渡到基于 CRISPR 的诊断检测，以实现对新出现的威胁的即时检测
  • 引入云端基础的生物资讯平台，用于分析和共用全球病原体威胁
  • 政府主导的资金用于扩大高防护设施的容量
  • 新兴的综合供应链弹性策略，以确保关键医疗用品的安全
  • 监管协调努力，简化新对策的紧急使用核准流程

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第八章 生物防御市场（依产品类型）

  • 净化产品
    • 消毒剂
    • 个人防护设备
  • 检测装置
    • 生物感测器
    • 病原体检测系统
  • 治疗药物
    • 抗病毒治疗
    • 单株抗体
  • 疫苗
    • 炭疽菌疫苗
    • 肉毒桿菌疫苗
    • 天花疫苗

9. 生物防御市场（依病原体类型）

  • 细菌因素
  • 毒素
  • 病毒因子

第 10 章。生物防御市场（按技术）

  • 免疫检测
  • 质谱法
  • 次世代定序
  • 聚合酵素链锁反应

第 11 章 生物防御市场（依应用）

  • 检测与诊断
  • 预防
  • 治疗

第 12 章 生物防御市场（依最终使用者）

  • 学术研究机构
  • 政府和国防机构
  • 医院和诊所
  • 製药和生物技术公司

第 13 章。生物防御市场（按分销管道）

  • 线下通路
  • 线上管道

第 14 章：美洲生物防御市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15.欧洲、中东和非洲生物防御市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第 16 章：亚太生物防御市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Emergent BioSolutions Inc.
    • Siga Technologies, Inc.
    • Xoma Corporation
    • Altimmune, Inc.
    • Dynavax Technologies Corporation
    • Elusys Therapeutics, Inc.
    • Ichor Medical Systems
    • DynPort Vaccine Company LLC
    • Luminex Corporation
    • Cleveland Biolabs Inc.
    • Bavarian Nordic A/S
    • Alnylam Pharmaceuticals, Inc.
    • QIAGEN NV
    • Ecolab Inc.
    • Abbott Laboratories
    • Bio-Rad Laboratories
    • Nova Biomedical Corporation
    • Siemens Healthcare
    • Strados Labs
    • Thermo Fisher Scientific
    • Biofourmis Singapore Pte. Ltd.
    • SD BIOSENSOR
    • Lucentix SA

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-434CCDA050CE

The Biodefense Market was valued at USD 20.33 billion in 2024 and is projected to grow to USD 22.71 billion in 2025, with a CAGR of 11.35%, reaching USD 38.77 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 20.33 billion
Estimated Year [2025] USD 22.71 billion
Forecast Year [2030] USD 38.77 billion
CAGR (%) 11.35%

In an era where biological threats can emerge and propagate with unprecedented speed and stealth, a comprehensive understanding of the biodefense ecosystem is more critical than ever. The global community faces a convergence of natural outbreaks, accidental releases, and deliberate malicious use of pathogens, creating a pressing need for robust detection, prevention, and response strategies. Against this backdrop, stakeholders across government, industry, and research institutions are accelerating investments in next-generation technologies and collaborative frameworks to shore up vulnerabilities at every point along the biodefense value chain.

This executive summary distills the most salient developments across product innovation, policy shifts, supply chain resilience, and strategic partnerships that are redefining preparedness. Through a structured analysis of transformative dynamics, trade policy implications, segment-level insights, and regional variations, the content provides a holistic perspective on how decision-makers can align resources and capabilities to emerging biothreat scenarios.

By tracing the interplay between technological advances and regulatory adaptations, this overview equips leaders with a clear roadmap for action. It highlights the mechanisms through which public-private synergies and international cooperation will shape the coming years. In doing so, it lays the groundwork for the detailed strategic recommendations, methodological disclosure, and concluding perspectives that follow, empowering organizations to bolster readiness and foster resilience in a rapidly evolving risk environment.

Identifying Major Transformative Dynamics Redefining Biodefense Readiness Capabilities and Industry Collaboration Across the Value Chain

The biodefense arena is being reshaped by a wave of groundbreaking innovations and novel collaborative models that collectively redefine what is possible in threat detection and response. Advances in synthetic biology and gene editing are delivering more sensitive diagnostic platforms, while artificial intelligence and machine learning optimize predictive analytics and accelerate the identification of emerging pathogens. These technological breakthroughs are not isolated; they are being integrated into expansive Internet of Things networks and cloud-based architectures, creating a seamless fabric of real-time surveillance and rapid situational awareness.

Equally significant has been the emergence of public-private consortiums and cross-sector partnerships designed to mobilize resources and expertise with unprecedented speed. By pooling laboratory capabilities from academic centers, defense programs, and commercial innovators, these collaborations are streamlining the path from discovery to deployment. At the same time, regulatory bodies are modernizing approval pathways and issuing adaptive guidance to ensure that critical countermeasures can be fielded without undue delay or compromise of safety standards.

A parallel shift has been underway in supply chain management, where resilience has taken precedence over cost-minimization. Organizations are investing in redundant manufacturing nodes and diversifying sourcing strategies for key reagents, protective equipment, and biologics. This emphasis on robustness extends into logistics, with specialized cold-chain networks and expedited distribution channels designed to maintain readiness under stress conditions.

Together, these transformative shifts form an integrated blueprint for a more agile and responsive biodefense ecosystem. By understanding these dynamics, stakeholders can better position themselves to harness the full potential of emerging technologies, regulatory flexibilities, and collaborative infrastructures.

Assessing the Comprehensive Implications of United States Tariff Adjustments Set to Take Effect in 2025 on Biodefense Procurements and Supply Chains

New tariff measures announced in the United States for 2025 will have far-reaching effects on the biodefense supply chain, procurement strategies, and domestic manufacturing incentives. Import duties on critical raw materials, diagnostic instruments, and specialized reagents are set to increase, directly affecting the cost structures of international suppliers and downstream integrators. This shift in trade policy is prompting organizations to revisit supplier relationships, cost negotiations, and inventory management practices to mitigate exposure to higher duties and logistical delays.

As a result, many stakeholders are accelerating plans to establish or expand onshore production facilities. Domestic manufacturing of detection devices, therapeutic antibodies, and vaccine adjuvants is being pursued not only to contain costs but also to enhance strategic autonomy in the face of cross-border restrictions. Policymakers are reinforcing these efforts by offering incentives such as tax credits, accelerated approval processes for localized production methods, and targeted research grants to underpin near-term scale-up projects.

Procurement agencies are also adapting their contracting frameworks to incorporate total-cost-of-ownership models that factor in tariff impacts, currency fluctuations, and potential supply disruptions. This holistic approach is enabling clearer decision criteria, balancing unit pricing with considerations for delivery lead times, quality assurance, and long-term regulatory compliance.

In the face of these policy shifts, stakeholders who proactively align manufacturing footprints, diversify import sources, and engage in strategic partnerships will be best positioned to sustain resilience. By leveraging domestic production incentives and adopting more integrated procurement strategies, organizations can navigate tariff pressures while safeguarding mission-critical capabilities.

Unveiling Key Segmentation Perspectives Spanning Product Types Pathogen Categories Technologies Applications End Users and Distribution Channels

The biodefense market is dissected through a multifaceted lens that encompasses product types, pathogen categories, technological platforms, application areas, end-user profiles, and distribution formats. Within the product spectrum, decontamination solutions are split between surface disinfectants and personal protective equipment, offering frontline defense against contamination. Detection platforms extend across biosensor arrays and pathogen detection systems, each calibrated for rapid, field-deployable screening or high-throughput laboratory diagnostics. Therapeutic offerings span antiviral therapies alongside monoclonal antibodies, reflecting both small molecule interventions and biologics designed for precision targeting. Vaccine formulations include those for anthrax, botulism, and smallpox, each tailored to specific biothreat scenarios and immunological profiles.

When viewed through the lens of pathogen type, the analysis covers bacterial agents, toxins, and viral threats, ensuring that countermeasure development is aligned with the biological characteristics and transmission pathways of diverse organisms. The technology domain explores immunoassays, mass spectrometry, next generation sequencing, and polymerase chain reaction modalities, illustrating how each platform contributes unique strengths in terms of sensitivity, specificity, and throughput.

Application analysis delineates detection and diagnostics from preventive strategies and therapeutic interventions, underscoring the continuum from early warning to clinical management. End-user segmentation highlights the differing operational needs of entities such as academic and research institutes, government and defense agencies, hospitals and clinics, and pharmaceutical and biotechnology companies. Finally, distribution channel differentiation between offline and online mechanisms sheds light on procurement preferences, logistical considerations, and the evolving role of e-commerce in life science supplies.

Through this comprehensive segmentation framework, stakeholders can pinpoint the precise intersections of need and capability, optimizing resource allocation and innovation focus within the broader biodefense ecosystem.

Highlighting Vital Regional Differentials and Strategic Biodefense Priorities Across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics in the biodefense arena diverge significantly, driven by distinct threat perceptions, budgetary allocations, and infrastructural capabilities. In the Americas, well-established defense programs and substantial federal research grants underpin a robust network of national laboratories and domestic manufacturers. This region's leading role in vaccine development, therapeutic research, and diagnostic platform innovation benefits from deep integration between academic centers and commercial entities. The presence of regulatory agencies with global influence further accelerates the approval and international deployment of critical countermeasures.

Europe, the Middle East, and Africa present a mosaic of regulatory frameworks and threat landscapes. European Union member states emphasize harmonized standards and cross-border data sharing, facilitating joint procurement and collaborative R&D initiatives. Meanwhile, Middle Eastern and African nations prioritize capacity building in public health infrastructure and border surveillance to address emerging zoonotic risks. Across this expanse, strategic partnerships with regional hubs are fostering knowledge transfer, training programs, and the establishment of rapid response teams equipped for both natural outbreak and bioterror scenarios.

The Asia-Pacific region has emerged as a focal point for manufacturing scale-up and technology transfer. Several economies in this zone are rapidly expanding vaccine production capabilities and investing in advanced sequencing and diagnostic platforms. Robust government funding, coupled with public health modernization drives, is creating a fertile environment for local innovators to partner with global defense contractors. As a result, supply chains are becoming more diversified, reducing reliance on traditional western hubs and strengthening regional resilience against disruption.

These regional insights underscore the necessity of tailoring strategies to local contexts. By recognizing the specific strengths and constraints of each zone, stakeholders can orchestrate more effective collaborations, optimize resource allocation, and ensure that critical biodefense capabilities are deployed where they are needed most.

Key Corporate Strategic Initiatives Technological Innovations and Collaborative Partnerships Shaping the Competitive Biodefense Landscape

Leading organizations within the biodefense landscape are distinguished by their multifaceted approaches to innovation, partnership, and commercialization. Large pharmaceutical and biotechnology firms have intensified their focus on next-generation vaccine platforms, antibody engineering, and antiviral drug development, leveraging advanced bioprocessing capabilities and robust regulatory track records. These incumbents have entered into strategic alliances with smaller specialized technology providers to accelerate development cycles and expand global reach.

In the diagnostic arena, companies specializing in biosensors and rapid pathogen detection systems are pioneering point-of-care solutions that combine miniaturized hardware with artificial intelligence-driven analytics. Their success in securing government contracts and defense grants underscores the shifting emphasis toward distributed surveillance models. At the same time, developers of decontamination products are integrating novel antimicrobial chemistries and self-sanitizing surface materials into personal protective equipment, addressing both health care and critical infrastructure requirements.

Collaborative ventures are also on the rise, as major defense contractors join forces with academic research centers and emerging life science startups to co-develop platforms spanning sequencing-based surveillance to mRNA-based vaccine technologies. Mergers and acquisitions remain a catalyst for portfolio diversification, enabling companies to rapidly fill gaps in their countermeasure pipelines.

Meanwhile, a new wave of agile startups is carving out niches in specialized detection chemistries and compact distribution systems. These ventures often secure seed funding through innovation grants and engage in pilot deployments with local government entities to validate performance under real-world conditions.

Overall, the competitive landscape is being reshaped by an interconnected web of established players and nimble newcomers, each contributing to a more comprehensive and resilient biodefense capability set.

Actionable Strategic Recommendations to Enhance Resilience Agility and Collaborative Readiness Within the Biodefense Ecosystem

To fortify biodefense readiness and drive sustained innovation, organizations should adopt a multipronged strategy that emphasizes early detection, supply chain robustness, and collaborative intelligence. First, investment in advanced diagnostic platforms such as high-throughput sequencing and AI-powered biosensor networks will enable faster threat identification and more precise epidemiological tracking. Embedding these technologies within decentralized testing hubs can further amplify detection coverage and reduce response latency.

Second, supply chain strategies must shift from lean-only models to hybrid frameworks that incorporate redundant domestic and international manufacturing nodes. This dual approach not only mitigates the risk of single-source disruptions but also leverages the benefits of localized production incentives and specialized export controls. Establishing clear protocols for rapid scale-up of critical reagents and equipment will ensure that production ramp-up aligns with evolving threat levels.

Third, fostering sustained public-private partnerships and cross-disciplinary consortiums will accelerate the translation of research breakthroughs into field-ready solutions. Regular scenario-based exercises, joint training programs, and data-sharing agreements among defense agencies, health authorities, and commercial entities will enhance collective preparedness and illuminate latent capability gaps.

Fourth, harnessing the power of data analytics to integrate surveillance data, procurement trends, and regulatory updates will support more informed decision making. Deploying centralized dashboards and interoperable information systems across stakeholder groups will facilitate real-time visibility into critical supply metrics and evolving threat signatures.

Finally, proactive engagement with regulatory authorities to align on adaptive approval pathways and emergency use authorizations will streamline deployment of novel countermeasures. By combining these strategic pillars, industry leaders can elevate resilience, agility, and anticipatory governance across the biodefense ecosystem.

Detailed Research Methodology Integrating Data Collection Expert Consultations and Rigorous Analytical Frameworks for Biodefense Market Insights

Our analysis relies on a comprehensive research framework that integrates both primary insights from industry experts and rigorous secondary data collection. Initial secondary research involved a systematic review of peer-reviewed publications, government white papers, regulatory filings, and patent databases to identify foundational trends and emerging technologies. These insights were then supplemented by detailed company profiles and financial disclosures to map out current competitive dynamics and investment flows.

In parallel, more than fifty hours of in-depth interviews were conducted with key opinion leaders, including senior executives from government agencies, defense integrators, academic researchers, and technology providers. These discussions were structured to validate secondary findings, uncover nuanced market drivers, and assess the practical efficacy of recently deployed solutions. A structured questionnaire was used to ensure consistency in data collection across stakeholder segments.

Quantitative validation was achieved through data triangulation, aligning input from primary sources with secondary indicators such as procurement announcements, public funding allocations, and clinical trial registries. This multilayered approach enhances the reliability of insights and reflects the dynamic interplay between innovation cycles and regulatory shifts.

To ensure methodological rigor, all data points underwent cross-verification by an independent research team. Potential limitations, including data lags and proprietary information gaps, were addressed through sensitivity analysis and scenario modeling. The result is a robust intelligence foundation designed to inform strategic planning, technology roadmapping, and policymaking in the biodefense domain.

Concluding Perspectives on Future Trajectories Prioritization of Preparedness and Emerging Innovations in the Global Biodefense Arena

As the global threat landscape continues to evolve, the imperative for cohesive and agile biodefense strategies has never been more apparent. The convergence of technological strides, shifting trade policies, and dynamic regional priorities demands a comprehensive approach that bridges detection, prevention, and response. Organizations that successfully integrate advanced diagnostic platforms with resilient supply chain models and adaptive regulatory pathways will be best positioned to counter both known and emergent biological risks.

Looking ahead, the trajectory of biodefense will be characterized by deeper integration of artificial intelligence, decentralized surveillance networks, and modular manufacturing capabilities. These innovations will require not only capital investment but also the cultivation of interdisciplinary talent pools and collaborative frameworks that transcend traditional sector boundaries.

Ultimately, the future of biodefense hinges on a balanced fusion of proactive threat mitigation and reactive response readiness. By harnessing the insights presented in this executive summary-ranging from transformative market shifts to actionable recommendations-stakeholders can refine their strategic playbooks and prioritize initiatives that deliver the greatest impact.

In closing, this synthesis underscores the essential role of ongoing collaboration, data-driven decision making, and regulatory alignment in forging a more resilient and adaptive biodefense ecosystem. It calls on leaders across government, industry, and research institutions to seize the strategic imperatives outlined herein and drive forward a collective commitment to safeguarding public health and national security.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of AI-driven pathogen detection platforms for real-time biodefense monitoring
  • 5.2. Surge in synthetic biology investments accelerating rapid vaccine development pipelines
  • 5.3. Deployment of field-compatible mobile laboratories transforming on-site biodefense response readiness
  • 5.4. Integration of genomic surveillance networks into national biodefense early warning systems
  • 5.5. Escalating partnerships between defense agencies and biopharmaceutical firms for countermeasure R&D
  • 5.6. Shift towards CRISPR-based diagnostic assays enabling point-of-care detection of emerging threats
  • 5.7. Adoption of cloud-based bioinformatics platforms for global pathogen threat analysis and sharing
  • 5.8. Government-led funding initiatives driving expansion of high-containment biodefense facilities capacity
  • 5.9. Emergence of holistic supply chain resilience strategies to secure critical biodefense medical supplies
  • 5.10. Regulatory harmonization efforts streamlining emergency use approval processes for novel countermeasures

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biodefense Market, by Product Type

  • 8.1. Introduction
  • 8.2. Decontamination Products
    • 8.2.1. Disinfectants
    • 8.2.2. PPE
  • 8.3. Detection Devices
    • 8.3.1. Biosensors
    • 8.3.2. Pathogen Detection Systems
  • 8.4. Therapeutics
    • 8.4.1. Antiviral Therapies
    • 8.4.2. Monoclonal Antibodies
  • 8.5. Vaccines
    • 8.5.1. Anthrax Vaccine
    • 8.5.2. Botulism Vaccine
    • 8.5.3. Smallpox Vaccine

9. Biodefense Market, by Pathogen Type

  • 9.1. Introduction
  • 9.2. Bacterial Agents
  • 9.3. Toxins
  • 9.4. Viral Agents

10. Biodefense Market, by Technology

  • 10.1. Introduction
  • 10.2. Immunoassays
  • 10.3. Mass Spectrometry
  • 10.4. Next Generation Sequencing
  • 10.5. Polymerase Chain Reaction

11. Biodefense Market, by Application

  • 11.1. Introduction
  • 11.2. Detection & Diagnostics
  • 11.3. Prevention
  • 11.4. Treatment

12. Biodefense Market, by End User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Government & Defense Agencies
  • 12.4. Hospitals & Clinics
  • 12.5. Pharma & Biotech Companies

13. Biodefense Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Offline Channels
  • 13.3. Online Channels

14. Americas Biodefense Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Biodefense Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Biodefense Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Emergent BioSolutions Inc.
    • 17.3.2. Siga Technologies, Inc.
    • 17.3.3. Xoma Corporation
    • 17.3.4. Altimmune, Inc.
    • 17.3.5. Dynavax Technologies Corporation
    • 17.3.6. Elusys Therapeutics, Inc.
    • 17.3.7. Ichor Medical Systems
    • 17.3.8. DynPort Vaccine Company LLC
    • 17.3.9. Luminex Corporation
    • 17.3.10. Cleveland Biolabs Inc.
    • 17.3.11. Bavarian Nordic A/S
    • 17.3.12. Alnylam Pharmaceuticals, Inc.
    • 17.3.13. QIAGEN N.V.
    • 17.3.14. Ecolab Inc.
    • 17.3.15. Abbott Laboratories
    • 17.3.16. Bio-Rad Laboratories
    • 17.3.17. Nova Biomedical Corporation
    • 17.3.18. Siemens Healthcare
    • 17.3.19. Strados Labs
    • 17.3.20. Thermo Fisher Scientific
    • 17.3.21. Biofourmis Singapore Pte. Ltd.
    • 17.3.22. SD BIOSENSOR
    • 17.3.23. Lucentix SA

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. BIODEFENSE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIODEFENSE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC BIODEFENSE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. BIODEFENSE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BIODEFENSE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. BIODEFENSE MARKET: RESEARCHAI
  • FIGURE 28. BIODEFENSE MARKET: RESEARCHSTATISTICS
  • FIGURE 29. BIODEFENSE MARKET: RESEARCHCONTACTS
  • FIGURE 30. BIODEFENSE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIODEFENSE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIODEFENSE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIODEFENSE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIODEFENSE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIODEFENSE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIODEFENSE MARKET SIZE, BY DISINFECTANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIODEFENSE MARKET SIZE, BY DISINFECTANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIODEFENSE MARKET SIZE, BY PPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIODEFENSE MARKET SIZE, BY PPE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIODEFENSE MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIODEFENSE MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN DETECTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN DETECTION SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIVIRAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIODEFENSE MARKET SIZE, BY ANTIVIRAL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIODEFENSE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIODEFENSE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIODEFENSE MARKET SIZE, BY ANTHRAX VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIODEFENSE MARKET SIZE, BY ANTHRAX VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIODEFENSE MARKET SIZE, BY BOTULISM VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIODEFENSE MARKET SIZE, BY BOTULISM VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIODEFENSE MARKET SIZE, BY SMALLPOX VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIODEFENSE MARKET SIZE, BY SMALLPOX VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIODEFENSE MARKET SIZE, BY BACTERIAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIODEFENSE MARKET SIZE, BY TOXINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIODEFENSE MARKET SIZE, BY TOXINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIODEFENSE MARKET SIZE, BY VIRAL AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIODEFENSE MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIODEFENSE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIODEFENSE MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIODEFENSE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIODEFENSE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIODEFENSE MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIODEFENSE MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION & DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIODEFENSE MARKET SIZE, BY DETECTION & DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIODEFENSE MARKET SIZE, BY PREVENTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIODEFENSE MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIODEFENSE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIODEFENSE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT & DEFENSE AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIODEFENSE MARKET SIZE, BY GOVERNMENT & DEFENSE AGENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIODEFENSE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIODEFENSE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIODEFENSE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIODEFENSE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIODEFENSE MARKET SIZE, BY OFFLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIODEFENSE MARKET SIZE, BY OFFLINE CHANNELS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIODEFENSE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIODEFENSE MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS BIODEFENSE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES BIODEFENSE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIODEFENSE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 273. FRANCE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. FRANCE BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. FRANCE BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 276. FRANCE BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 277. FRANCE BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. FRANCE BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 279. FRANCE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 281. FRANCE BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 283. FRANCE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 285. FRANCE BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 287. FRANCE BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. FRANCE BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 289. FRANCE BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. FRANCE BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. FRANCE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 293. RUSSIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 295. RUSSIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 296. RUSSIA BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 297. RUSSIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 298. RUSSIA BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 299. RUSSIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 301. RUSSIA BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 303. RUSSIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 305. RUSSIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 307. RUSSIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 309. RUSSIA BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 311. RUSSIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 313. ITALY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. ITALY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 317. ITALY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 319. ITALY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 321. ITALY BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 323. ITALY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ITALY BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 325. ITALY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 327. ITALY BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. ITALY BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 329. ITALY BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. ITALY BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 331. ITALY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. ITALY BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 333. SPAIN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. SPAIN BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 335. SPAIN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 336. SPAIN BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 337. SPAIN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 338. SPAIN BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 339. SPAIN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 340. SPAIN BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 341. SPAIN BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 342. SPAIN BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 343. SPAIN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. SPAIN BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 345. SPAIN BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 346. SPAIN BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 347. SPAIN BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 348. SPAIN BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 349. SPAIN BIODEFENSE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. SPAIN BIODEFENSE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 351. SPAIN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 352. SPAIN BIODEFENSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 353. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 354. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DECONTAMINATION PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY DETECTION DEVICES, 2025-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 364. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY PATHOGEN TYPE, 2025-2030 (USD MILLION)
  • TABLE 365. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES BIODEFENSE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)

TAB